Log in

NASDAQ:SPHS - Sophiris Bio Stock Price, Forecast & News

$0.27
-0.03 (-10.00 %)
(As of 04/1/2020 06:12 AM ET)
Today's Range
$0.23
Now: $0.27
$0.35
50-Day Range
$0.10
MA: $0.49
$0.76
52-Week Range
$0.10
Now: $0.27
$1.17
Volume255,822 shs
Average Volume420,650 shs
Market Capitalization$9.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Read More
Sophiris Bio logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.06 per share

Profitability

Net Income$-6,780,000.00

Miscellaneous

Employees6
Market Cap$9.60 million
Next Earnings Date4/1/2020 (Estimated)
OptionableOptionable

Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter.


Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions

How has Sophiris Bio's stock been impacted by COVID-19 (Coronavirus)?

Sophiris Bio's stock was trading at $0.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SPHS shares have increased by 17.4% and is now trading at $0.27. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sophiris Bio?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sophiris Bio.

When is Sophiris Bio's next earnings date?

Sophiris Bio is scheduled to release its next quarterly earnings announcement on Wednesday, April 1st 2020. View our earnings forecast for Sophiris Bio.

How were Sophiris Bio's earnings last quarter?

Sophiris Bio Inc (NASDAQ:SPHS) issued its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. View Sophiris Bio's earnings history.

What price target have analysts set for SPHS?

2 brokerages have issued 1 year price objectives for Sophiris Bio's stock. Their forecasts range from $2.80 to $6.00. On average, they anticipate Sophiris Bio's stock price to reach $4.40 in the next twelve months. This suggests a possible upside of 1,529.6% from the stock's current price. View analysts' price targets for Sophiris Bio.

Has Sophiris Bio been receiving favorable news coverage?

News headlines about SPHS stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sophiris Bio earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View the latest news aboutSophiris Bio.

Who are some of Sophiris Bio's key competitors?

What other stocks do shareholders of Sophiris Bio own?

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the following people:
  • Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 69)
  • Mr. Randall E. Woods, CEO, Pres & Director (Age 67)
  • Mr. Peter T. Slover, Chief Financial Officer (Age 44)
  • Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 56)
  • Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $0.27.

How big of a company is Sophiris Bio?

Sophiris Bio has a market capitalization of $9.60 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe. View additional information about Sophiris Bio.

What is Sophiris Bio's official website?

The official website for Sophiris Bio is http://www.sophirisbio.com/.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]


MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  483
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: Moving Average (MA)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel